Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Amphastar Pharmaceuticals, Inc. (AMPH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $19.15 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $19.21, a 32.38% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $28.41, a 39.14% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $46.68, a 32.88% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $35.13, a 1.12% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $28.16, a 39.14% decline from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $46.27, a 29.10% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $35.84, a 4.34% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $34.35, a 88.12% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.15 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $19.21 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $28.16 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $28.17 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $28.21 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $28.41 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $46.27 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $46.27 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $46.27 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | $46.68 10-Q · filed 2024-05-10 | |||
| 2023-12-31 | $35.84 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $35.84 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $35.83 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $35.13 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $34.35 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $34.35 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $34.36 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $34.74 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $18.26 10-K · filed 2022-03-11 | |||
| 2021-09-30 | $18.25 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $18.22 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $17.99 10-Q · filed 2021-05-07 | |||
| 2020-12-31 | $13.57 10-K · filed 2021-03-15 | |||
| 2020-09-30 | $13.56 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | $13.52 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $13.03 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $20.98 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $20.99 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | $20.96 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $21.04 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $20.16 10-K · filed 2019-03-15 | |||
| 2018-09-30 | $20.15 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $20.16 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $20.59 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $14.23 10-K · filed 2018-03-14 | |||
| 2017-09-30 | $14.23 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $14.19 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | $13.93 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $12.19 10-K · filed 2017-03-15 | |||
| 2016-09-30 | $12.19 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $12.15 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $11.85 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $15.70 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $15.71 10-Q · filed 2015-11-13 | |||
| 2015-06-30 | $15.71 10-Q · filed 2015-08-13 | |||
| 2015-03-31 | $15.81 10-Q · filed 2015-05-14 | |||
| 2014-12-31 | $15.04 10-K · filed 2016-03-15 | |||
| 2014-09-30 | $15.04 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $15.04 10-Q · filed 2014-08-13 | |||
| 2013-12-31 | $12.09 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |